Information about Psychoactive Medication

  • 2 Replies
  • 98 Views
*

Kizzie

  • Administrator
  • Member
  • 7126
    • View Profile
Information about Psychoactive Medication
« on: June 13, 2019, 12:13:36 AM »
MAPS (Multidisciplinary Association for Psychedelic Studies) - a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials, May 2019.  Note: This article concerns MDMA trials for PTSD vs Complex PTSD

Statement: Considerations for the Regulation and Decriminalization of Psychedelic Substances, May 31, 2019. By Natalie Lyla Ginsberg, M.S.W., and Ismail Lourido Ali, J.D.

Scientists are reclaiming psychedelics as “wonder drugs.” Is it time to decriminalize them?,  June 6, 2019 - Video by Michael Tabb
« Last Edit: June 13, 2019, 12:19:08 AM by Kizzie »

*

Kizzie

  • Administrator
  • Member
  • 7126
    • View Profile
Re: Information about Psychoactive Medication
« Reply #1 on: July 15, 2019, 09:16:45 PM »
TED talk by Rick Doblin, founder of MAPS (Multidisciplinary Association for Psychedelic Studies)"

"The Future of Psychedelic-assisted Psychotherapy"

*

Kizzie

  • Administrator
  • Member
  • 7126
    • View Profile
Re: Information about Psychoactive Medication
« Reply #2 on: August 01, 2019, 12:43:49 PM »
Psychedelic Medicine Is Coming. The Law Isn’t Ready - "A surprising resurgence of psychedelic research has produced its first FDA-approved treatment, with more likely on the way" by Matt Lamkin, July 31, 2019.

Excerpt:


The prospect of psychedelic drugs gaining approval as treatments will force a reckoning for our existing system of drug control. While current policies characterize any use of these substances as illicit abuse, acknowledging that these drugs may offer meaningful benefits will require more flexible approaches. Psychedelic medicine may prove to be the thin end of a wedge that moves drug policy away from the elusive goal of eradication in favor of more nuanced strategies that harness the benefits of psychotropic drugs while minimizing their risks.